(INTREPID-1) A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Dexamethasone (Primary) ; Oprozomib (Primary) ; Oprozomib (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms INTREPID-1
- Sponsors Amgen
- 18 Oct 2022 Status changed from active, no longer recruiting to completed.
- 21 Dec 2021 Planned End Date changed from 23 Dec 2021 to 23 Dec 2022.
- 21 Dec 2021 Planned primary completion date changed from 23 Dec 2021 to 23 Dec 2022.